<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278614</url>
  </required_header>
  <id_info>
    <org_study_id>LT2347-PIII-12/13</org_study_id>
    <nct_id>NCT02278614</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients</brief_title>
  <official_title>Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005%
      + Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous
      patients initially treated, stabilised by Xalacom® or generics (fixed combination Latanoprost
      0.005% + Timolol 0.5% preserved eye drops).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, international, multicentre, randomised, investigator masked, 3 month duration, 2
      parallel groups, 2 X 97 evaluable patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye</measure>
    <time_frame>Day 84</time_frame>
    <description>the non-inferiority of T2347 unpreserved eye drops compared with Xalacom® on change in mean IOP at 9.00 am (± 1 hour) between the baseline (Day 0) and Day 84 in the worse eye.
Two relevant time points are considered for this primary criteria: D0 and Day 84.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>T2347</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalacom</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T2347</intervention_name>
    <description>T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.</description>
    <arm_group_label>T2347</arm_group_label>
    <other_name>Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalacom</intervention_name>
    <description>Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.</description>
    <arm_group_label>Xalacom</arm_group_label>
    <other_name>Latanoprost 0.005% + Timolol 0.5% preserved eye drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent,

          -  Male or female aged &gt; 18 years old,

          -  Both eyes with open angle glaucoma or ocular hypertension already treated and
             controlled by Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol
             0.5% preserved eye drops) since at least 2 months.

          -  IOP ≤ 18 mmHg in both eyes

          -  History of IOP insufficiently controlled with first-line monotherapy based on the
             investigator judgement (e.g. non reaching the target IOP)

          -  History of an add-on IOP reduction with Xalacom® or generics (fixed combination
             Latanoprost 0.005% + Timolol 0.5% preserved eye drops) in comparison with first-line
             treatment

          -  Corneal thickness ≥ 500 μm and ≤ 600 μm in both eyes.

        Exclusion Criteria:

          -  Ophthalmic exclusion criteria (in either eye)

          -  Fundoscopy, VF not performed or not available within the 6 months before inclusion
             visit.

          -  Significant worsening according to the two last VF (minimum 6 months between these 2
             VF)

          -  Advanced stage of glaucoma:

          -  Best far corrected visual acuity ≤ 1/10.

          -  History of trauma, infection, clinically significant inflammation within the 3 months
             before inclusion visit.

          -  Ongoing or known history of ocular seasonal and perennial allergy (SAC, PAC) and/or
             uveitis and/or viral infection.

          -  Presence of at least one severe objective sign among the following:

               -  Hyperaemia (Grade 5)

               -  Superficial punctate keratitis (Grade 3)

               -  Blepharitis (Grade 3)

          -  Severe dry eye (defined by severe epithelial erosions of the cornea and/or use of dry
             eye medication with a frequency exceeding 8 instillations / day).

          -  Corneal ulceration.

          -  Palpebral abnormalities not related to medical treatment study and incompatible with a
             good evaluation.

          -  History of corneal refractive surgery.

          -  Any abnormality preventing accurate assessment e.g. reliable tonometry measurement,
             visual field examination.

        Systemic/non ophthalmic exclusion criteria

          -  Non-controlled diabetic patient.

          -  Reactive airway disease including bronchial asthma or a history of bronchial asthma,
             severe chronic obstructive pulmonary disease.

          -  Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree
             atrioventricular block not controlled with pace-maker, overt cardiac failure,
             cardiogenic shock.

          -  Heart rate &lt;50 bpm, systolic arterial blood pressure≤ 90 mm Hg

          -  Known or suspected hypersensitivity to one of the components of the study product.

          -  Any medical or surgical history, disorder or disease such as acute or chronic severe
             organic disease: hepatic, endocrine, neoplastic, haematological; immunosuppressive,
             infectious diseases, severe psychiatric illness, relevant cardiovascular
             abnormalities, etc… and/or any complicating factor or structural abnormality, judged
             by the investigator to be incompatible with the study.

        Specific exclusion criteria for women

          -  Pregnancy, lactation.

          -  Childbearing potential woman who is not using a reliable method of contraception

        Exclusion criteria related to general conditions

          -  Inability of patient to understand the study procedures and thus inability to give
             informed consent.

          -  Non-compliant patient

          -  Participation in another clinical study with investigational drug within the last 3
             months.

          -  Already included once in this study.

          -  Patients being institutionalised because of legal or regulatory order, inmates of
             psychiatric wards, prison or state institutions, and employees of the study sites or
             of the Sponsor's company.

          -  Ward of court.

          -  Patient not covered by government health care scheme in the country (if applicable).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingeborg Stalmans, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Glaucoma Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratoires Thea</name>
      <address>
        <city>Clermont ferrand</city>
        <zip>63017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <results_first_submitted>November 24, 2016</results_first_submitted>
  <results_first_submitted_qc>November 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2017</results_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T2347</title>
          <description>T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
T2347: T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.</description>
        </group>
        <group group_id="P2">
          <title>Xalacom</title>
          <description>Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
Xalacom: Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>left eye was not eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T2347</title>
          <description>T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
T2347: T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.</description>
        </group>
        <group group_id="B2">
          <title>Xalacom</title>
          <description>Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
Xalacom: Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="10.8"/>
                    <measurement group_id="B2" value="67.2" spread="10.6"/>
                    <measurement group_id="B3" value="66.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye</title>
        <description>the non-inferiority of T2347 unpreserved eye drops compared with Xalacom® on change in mean IOP at 9.00 am (± 1 hour) between the baseline (Day 0) and Day 84 in the worse eye.
Two relevant time points are considered for this primary criteria: D0 and Day 84.</description>
        <time_frame>Day 84</time_frame>
        <population>The primary efficacy analysis (mean change in IOP from baseline to Day 84) was performed on the mITT set (236 patients).
mITT set: All ITT patients with at least one baseline and one post-randomisation efficacy assessment following study treatment.
242 patients described in the participant flow correpsond to the ITT &amp; Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>T2347</title>
            <description>T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
T2347: T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.</description>
          </group>
          <group group_id="O2">
            <title>Xalacom</title>
            <description>Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
Xalacom: Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye</title>
          <description>the non-inferiority of T2347 unpreserved eye drops compared with Xalacom® on change in mean IOP at 9.00 am (± 1 hour) between the baseline (Day 0) and Day 84 in the worse eye.
Two relevant time points are considered for this primary criteria: D0 and Day 84.</description>
          <population>The primary efficacy analysis (mean change in IOP from baseline to Day 84) was performed on the mITT set (236 patients).
mITT set: All ITT patients with at least one baseline and one post-randomisation efficacy assessment following study treatment.
242 patients described in the participant flow correpsond to the ITT &amp; Safety set.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.18"/>
                    <measurement group_id="O2" value="-0.52" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The change from baseline in mean IOP on Day 84 for the contralateral eye,</non_inferiority_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The change from baseline in mean IOP on D42 for the worse eye</non_inferiority_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>T2347</title>
          <description>T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
T2347: T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.</description>
        </group>
        <group group_id="E2">
          <title>Xalacom</title>
          <description>Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
Xalacom: Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Medical Operations</name_or_title>
      <organization>Laboratoires Théa</organization>
      <phone>04 73 98 50 89</phone>
      <email>J.AUGER@laboratoires-thea.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

